Arndt Vogel: Lenvatinib Plus Pembrolizumab Plus CTx vs CTx in Advanced Gastroesophageal Adenocarcinoma
Arndt Vogel, Head of the Center for Personalized Medicine, MHH at Hannover Medical School, shared a post on X about a recent article by Kohei Shitara et al. published in JCO:
“Lenvatinib Plus Pembrolizumab + CTx vs CTx in advanced Gastroesophageal Adenocarcinoma
LEAP-015 Study phase III
- ORR 59.5%vs 45.4%
- mPFS 7.2 vs 7.0 mo
- mOS 13.1 vs 13.0 mo
Negative study, no benefit, more toxicity. ”
Title: Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study
Journal: JCO
Authors: Kohei Shitara, Sylvie Lorenzen, Jin Li, Yuxian Bai, Manuel González Fernández, Mynor Aguilar, Hirokazu Shoji, Felipe Reyes-Cosmelli, Yovany Rodriguez Peña, Luis Corrales, Lucjan Wyrwicz, Daniel Acosta Eyzaguirre, Yueyin Pan, Min-Hee Ryu, Deirdre J. Cohen, Zev A. Wainberg, Geoffrey Ku, Josep Tabernero, Eric Van Cutsem, Shu-Kui Qin, Do-Youn Oh, Jianming Xu, Li Wen Liang, Sonal Bordia, Pooja Bhagia, Sun Young Rha
More posts featuring Arndt Vogel on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023